Summary
We have treated 25 patients, 7 with breast cancer and 18 with non-Hodgkin's lymphoma, with recombinant alpha2 interferon. In 5 patients we observed cardiac arrhythmias that were unexpected and required treatment. No deaths have occured that we can attribute to interferon, though 1 patient had to be resuscitated. Age, prior cardiac disease, prior treatment with doxorubicin, and interferon dose appear to be predisposing factors for this toxicity.
Similar content being viewed by others
References
Blalock JE, Stanton JD (1980) Common pathways of interferon and hormonal action. Nature 283:406–408
Budd GT, Bukowski RM, Miketo L, Yen-Lieberman B, Proffitt MR (1984) Phase-I trial of ultrapure human leukocyte interferon in human malignancy. Cancer Chemother Pharmacol 12:39–42
Calvet MC, Gresser I (1979) Interferon enhances the excitability of cultured neurons. Nature 278:558–560
Dickson D (1982) Death halts interferon trials in France. Science 218:772
Foon KA, Sherwin SA, Abrams PG, Longo DL, Fer MF, Stevenson HC, Ochs JJ, Bottino GC, Schoenberger CS, Zeffren J, Jaffe ES, Oldham RK (1984) Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon. New Engl J Med 311:1148–1152
Kirkwood JM, Ernstoff MS (1984) Interferons in the treatment of human cancer. J Clin Oncol 2(4):336–349
Lampidis TJ, Brouty-Boye D (1981) Interferon inhibits cardiac cell function in vitro. Proc Soc Exp Biol Med 166:181–185
Sarna G, Figlin R, Callaghan M (1983) (Human Leukocyte)-interferon as treatment for non-small cell carcinoma of the lung: a phase II trial. J Biol Response Mod 2(4):343–347
Usui N (1983) Clinical trial of human lymphoblastoid interferon on advanced malignancy. Gan To Kagaku Ryoho 10(11):2324–2329
Author information
Authors and Affiliations
Additional information
Supported by the Schering Corporation and Harper-Grace Hospitals
Rights and permissions
About this article
Cite this article
Martino, S., Ratanatharathorn, V., Karanes, C. et al. Reversible arrhythmias observed in patients treated with recombinant alpha2 interferon. J Cancer Res Clin Oncol 113, 376–378 (1987). https://doi.org/10.1007/BF00397722
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00397722